Merck
MRK
#39
Rank
โ‚ฌ324.12 B
Marketcap
131,48ย โ‚ฌ
Share price
0.06%
Change (1 day)
64.46%
Change (1 year)

P/E ratio for Merck (MRK)

P/E ratio as of November 2026 (TTM): 145

According to Merck's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 145.472. At the end of 2025 the company had a P/E ratio of 14.4.

P/E ratio history for Merck from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202514.4-0.33%
202414.4-97.87%
20236793674.95%
202218.034.71%
202113.4-44.9%
202024.227.46%
201919.0-25.19%
201825.4-44.27%
201745.6116.87%
201621.0-11.64%
201523.8152.83%
20149.42-58.32%
201322.686.02%
201212.16.11%
201111.4

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
42.3-70.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
30.5-79.02%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
40.6-72.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
39.7-72.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
46.3-68.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
26.6-81.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
24.4-83.20%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
13.9-90.43%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
17.5-87.96%๐Ÿ‡ฌ๐Ÿ‡ง UK
Teva Pharmaceutical Industries
TEVA
94.6-34.97%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.